CYTRX CORP
S-1, EX-27.1, 2000-06-21
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: CYTRX CORP, S-1, EX-23.1, 2000-06-21
Next: CYTRX CORP, S-1, EX-27.2, 2000-06-21



<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
<RESTATED>

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               DEC-31-1999
<CASH>                                       3,031,893
<SECURITIES>                                         0
<RECEIVABLES>                                  174,292
<ALLOWANCES>                                         0
<INVENTORY>                                      6,480
<CURRENT-ASSETS>                             3,415,275
<PP&E>                                       3,169,332
<DEPRECIATION>                               (527,522)
<TOTAL-ASSETS>                               6,128,063
<CURRENT-LIABILITIES>                        2,751,737
<BONDS>                                              0
                                0
                                          0
<COMMON>                                         8,374
<OTHER-SE>                                   1,024,314
<TOTAL-LIABILITY-AND-EQUITY>                 6,128,063
<SALES>                                        322,536
<TOTAL-REVENUES>                             1,391,460
<CGS>                                                0
<TOTAL-COSTS>                                  239,840
<OTHER-EXPENSES>                            16,421,538
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                           (15,269,918)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                       (15,269,918)
<DISCONTINUED>                                 240,627
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                              (15,029,291)
<EPS-BASIC>                                     (1.96)
<EPS-DILUTED>                                   (1.96)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission